Decoglurant

Decoglurant

Clinical data
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name 5-({7-(Trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}ethynyl)-2-pyridinamine
CAS Number	911115-16-7
PubChem CID	71533696
ChemSpider	32695160
UNII	5VX4P0JKC5
KEGG	D10875
Chemical and physical data
Formula	C21H11F6N5
Molar mass	447.344 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CN=C(C=C4)N)C(F)(F)F
InChI InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29) Key:DMJHZVARRXJSEG-UHFFFAOYSA-N

Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu₂ and mGlu₃ receptors which was under development by Roche for the adjunctive treatment of major depressive disorder. Decoglurant progressed as far as phase II clinical trials but was ultimately discontinued from further development due to disappointing efficacy results.

See also

• Basimglurant
• RO4491533

External links

• Decoglurant – AdisInsight – Springer